Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biocytogen Raises $142 Million for Gene-Modified Animal CRO Services

publication date: Sep 16, 2020

Beijing-based Biocytogen completed a $142 million Series D+ round led by returning investor CMB International. Biocytogen is a CRO that provides gene-modified animal models for drug discovery and preclinical testing. Founded in 2008, Biocytogen has branches in Beijing, Haimen /Jiangsu, Shanghai and Boston. The company generates custom gene-modified animal models/cell lines used for immunoncology molecules and therapeutic antibodies. One year ago, Biocytogen closed a $77 million Series D venture round. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital